Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma

Fig. 8

EFNA3 regulate the proliferation ability and glycolytic capacity of A549 cells. mRNA (A) and protein (B) expression levels of EFNA3 in human bronchial epithelial cells (HBE) and lung adenocarcinoma cells (H1299, H1975, A549, PC9, and HCC827). C EFNA3 expression levels were detected by qRT-PCR (left) and western blotting (right) analyses after transfection with negative control (NC) or EFNA3-siRNA; D Cell viability assays showed that EFNA3 knockdown decreased A549 cell proliferation; E The number of colonies formed by A549 cells transfected with EFNA3‐siRNA was lower than that for cells transfected with NC. F Lactate production, ATP level, and glucose uptake were measured in A549 cells after transfection with negative control (NC) or EFNA3-siRNA. G EFNA3 expression levels were detected by qRT-PCR (left) and western blotting (right) analyses after transfection with negative control (pcDNA3.1-NC) or pcDNA3.1-EFNA3; H Cell viability assays showed that EFNA3 overexpression increased HCC827 cell proliferation; I The number of colonies formed by HCC827 cells transfected with pcDNA3.1-EFNA3was higher than that for cells transfected with pcDNA3.1-NC; J Lactate production, ATP level, and glucose uptake were measured in HCC827 cells after transfection with negative control (pcDNA3.1-NC) or pcDNA3.1-EFNA3. mean ± SD; *p < 0.05, **p < 0.01, and ***p < 0.001 (vs. control group)

Back to article page